Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Lab Gains CAP Accreditation

NEW YORK (GenomeWeb News) – Diagnostics developer Asuragen said today that is has received accreditation as a CLIA-compliant lab by the College of American Pathologists (CAP).

The Austin, Texas-based firm said that the CAP accreditation is "a crucial step" in its plans to begin commercializing its miRNA-based oncology and clinical sample testing services.

"This is a significant step forward in our efforts to bring novel molecular diagnostic tests for oncology to market, and to offer our pharmaceutical clients a means to develop and validate companion diagnostic tests," Asuragen CEO Matt Winkler said in a statement.

The company currently is preparing its miRNA Pancreatic FFPE Test for diagnosing pancreatic adenocarcinoma.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.